{"id":4842,"date":"2012-05-14T10:05:00","date_gmt":"2012-05-14T07:05:00","guid":{"rendered":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2026\/01\/19\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\/"},"modified":"2026-01-19T11:09:32","modified_gmt":"2026-01-19T08:09:32","slug":"sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda","status":"publish","type":"post","link":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2012\/05\/14\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\/","title":{"rendered":"SGK BA\u015eKANLI\u011eININ DANI\u015eTAY KARARI VE D\u0130YAL\u0130Z HASTALARININ TETK\u0130K BELGELER\u0130 \u0130LE \u0130LG\u0130L\u0130 DUYURUSU HAKKINDA"},"content":{"rendered":"<div style=\"padding-bottom: 100px; margin: auto; width: 90%; display: flex; justify-content: center; flex-direction: column;\">\n<p>B\u00d6LGE ECZACI ODASI<\/p>\n<p>Y\u00d6NET\u0130M KURULU BA\u015eKANLI\u011eINA<\/p>\n<p>T.C.Sosyal G\u00fcvenlik Kurumu Ba\u015fkanl\u0131\u011f\u0131 Genel Sa\u011fl\u0131k Sigortas\u0131 Genel M\u00fcd\u00fcrl\u00fc\u011f\u00fc taraf\u0131ndan, www.sgk.gov.tr de 11.05.2012 tarihinde yay\u0131mlanan ve ekte bir \u00f6rne\u011fi yer alan duyuru ile,<\/p>\n<p>1- Dan\u0131\u015ftay Onuncu Dairesinin Karar\u0131 ile, 25\/3\/2010 tarihli ve 27532 m\u00fckerrer say\u0131l\u0131 Resm\u00ee Gazetede yay\u0131mlanan Sosyal G\u00fcvenlik Kurumu Sa\u011fl\u0131k Uygulama Tebli\u011finin, 05\/11\/2011 tarih ve 28106 say\u0131l\u0131 Resm\u00ee Gazetede yay\u0131mlanan Sosyal G\u00fcvenlik Kurumu Sa\u011fl\u0131k Uygulama Tebli\u011finde De\u011fi\u015fiklik Yap\u0131lmas\u0131na Dair Tebli\u011fin 10 numaral\u0131 maddesi ile 6.1.1.\u00c7 maddesine eklenen 7 nci f\u0131kras\u0131nda yer alan \u201c28\u201d ve \u201c29\u201d ibarelerinin y\u00fcr\u00fct\u00fcm\u00fcn\u00fcn durduruldu\u011fu, 11\/05\/2012 tarihinden ba\u015flayarak Sa\u011fl\u0131k Uygulama Tebli\u011finin ilgili maddesinin bu do\u011frultuda y\u00fcr\u00fct\u00fclece\u011fi,<\/p>\n<p>2- 23.1.2012 tarih, 28180 say\u0131l\u0131 Resmi Gazetede yay\u0131mlanan Sosyal G\u00fcvenlik Kurumu Sa\u011fl\u0131k Uygulama Tebli\u011finde De\u011fi\u015fiklik Yap\u0131lmas\u0131na Dair Tebli\u011fi ile 6.1.1.\u00c7-Re\u00e7etelere yaz\u0131labilecek ila\u00e7 miktarlar\u0131 ba\u015fl\u0131kl\u0131 maddesine \u201cHastan\u0131n tedavisinde ilk defa re\u00e7ete edilecek ila\u00e7lar (raporlu olsa dahi) en fazla 1 ayl\u0131k doza kadar \u00f6denir. Sonraki re\u00e7etelerde yaz\u0131lacak ila\u00e7 miktar\u0131 i\u00e7in tebli\u011fde yer alan genel veya \u00f6zel d\u00fczenlemeler esas al\u0131n\u0131r. Bu ila\u00e7lar\u0131n devam re\u00e7etelerindeki farkl\u0131 farmas\u00f6tik dozlar\u0131 da ilk tedavi olarak kabul edilir.\u201d \u015feklinde d\u00fczenlemenin (8) numaral\u0131 f\u0131kra olarak ilave edildi\u011fi ve 28.1.2012 tarihi itibariyle y\u00fcr\u00fcrl\u00fc\u011fe girdi\u011fi, Ancak, diyaliz hastalar\u0131nda tetkik sonucuna istinaden re\u00e7ete edilen ila\u00e7lar\u0131n bir ay ve daha k\u0131sa doz i\u00e7in re\u00e7ete edilmesi halinde, Sa\u011fl\u0131k Uygulama Tebli\u011finde tarif edilen s\u00fcre i\u00e7erisinde yap\u0131lm\u0131\u015f tetkikin fotokopisinin, bir aydan daha uzun s\u00fcreli doz i\u00e7in re\u00e7ete edilmesi halinde ise ayn\u0131 tetkikin asl\u0131n\u0131n re\u00e7eteye eklenmesinin m\u00fcmk\u00fcn oldu\u011fu,<\/p>\n<p>bildirilmi\u015ftir.<\/p>\n<p>Bilgilerinizi ve konunun \u00fcyelerinize duyurulmas\u0131n\u0131 sayg\u0131lar\u0131mla rica ederim.<\/p>\n<p>Uzm.Ecz.Harun KIZILAY<\/p>\n<p>Genel Sekreter<\/p>\n<p><font color=\"#ff0000\"><strong>SUT 6.1.1 \u00c7 Maddesi: <\/strong><\/font><\/p>\n<p><font color=\"#ff0000\"><strong>\u2026\u2026\u2026.. <\/strong><\/font><\/p>\n<p><font color=\"#ff0000\"><strong>(7) (Ek: 05\/11\/2011-28106\/10 md. Y\u00fcr\u00fcrl\u00fck:17\/11\/2011) Tebli\u011fdeki \u201c1 ayl\u0131k doz\u201d; 28, 29 ve 30 g\u00fcnl\u00fck kullan\u0131m s\u00fcrelerini ifade eder. <\/strong><\/font><\/p>\n<p><font color=\"#ff0000\"><strong>(8) (Ek: 21\/01\/2012-28180 \/20 md. Y\u00fcr\u00fcrl\u00fck: 28\/01\/2012) Hastan\u0131n tedavisinde ilk defa re\u00e7ete edilecek ila\u00e7lar (raporlu olsa dahi) en fazla 1 ayl\u0131k doza kadar \u00f6denir. Sonraki re\u00e7etelerde yaz\u0131lacak ila\u00e7 miktar\u0131 i\u00e7in tebli\u011fde yer alan genel veya \u00f6zel d\u00fczenlemeler esas al\u0131n\u0131r. Bu ila\u00e7lar\u0131n devam re\u00e7etelerindeki farkl\u0131 farmas\u00f6tik dozlar\u0131 da ilk tedavi olarak kabul edilir. <\/strong><\/font><\/p>\n<p> <a href=\"http:\/\/www.teb.org.tr\/images\/upld2\/haberler\/IEc20120514081121DUY.pdf\">http:\/\/www.teb.org.tr\/images\/upld2\/haberler\/IEc20120514081121DUY.pdf<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>B\u00d6LGE ECZACI ODASI Y\u00d6NET\u0130M KURULU BA\u015eKANLI\u011eINA T.C.Sosyal G\u00fcvenlik Kurumu Ba\u015fkanl\u0131\u011f\u0131 Genel Sa\u011fl\u0131k Sigortas\u0131 Genel M\u00fcd\u00fcrl\u00fc\u011f\u00fc taraf\u0131ndan, www.sgk.gov.tr de 11.05.2012 tarihinde yay\u0131mlanan ve ekte bir \u00f6rne\u011fi yer alan duyuru ile, 1- Dan\u0131\u015ftay Onuncu Dairesinin Karar\u0131 ile, 25\/3\/2010 tarihli ve 27532 m\u00fckerrer say\u0131l\u0131 Resm\u00ee Gazetede yay\u0131mlanan Sosyal G\u00fcvenlik Kurumu Sa\u011fl\u0131k Uygulama Tebli\u011finin, 05\/11\/2011 tarih ve 28106 say\u0131l\u0131 Resm\u00ee Gazetede yay\u0131mlanan Sosyal G\u00fcvenlik Kurumu Sa\u011fl\u0131k Uygulama Tebli\u011finde De\u011fi\u015fiklik Yap\u0131lmas\u0131na Dair Tebli\u011fin 10 numaral\u0131 maddesi ile 6.1.1.\u00c7 maddesine eklenen 7 nci f\u0131kras\u0131nda yer alan \u201c28\u201d ve \u201c29\u201d ibarelerinin y\u00fcr\u00fct\u00fcm\u00fcn\u00fcn durduruldu\u011fu, 11\/05\/2012 tarihinden ba\u015flayarak Sa\u011fl\u0131k Uygulama Tebli\u011finin ilgili maddesinin bu do\u011frultuda y\u00fcr\u00fct\u00fclece\u011fi, 2- 23.1.2012 tarih, 28180 say\u0131l\u0131 Resmi Gazetede yay\u0131mlanan Sosyal G\u00fcvenlik Kurumu Sa\u011fl\u0131k Uygulama Tebli\u011finde De\u011fi\u015fiklik Yap\u0131lmas\u0131na Dair Tebli\u011fi ile 6.1.1.\u00c7-Re\u00e7etelere yaz\u0131labilecek ila\u00e7 miktarlar\u0131 ba\u015fl\u0131kl\u0131 maddesine \u201cHastan\u0131n tedavisinde ilk defa re\u00e7ete edilecek ila\u00e7lar (raporlu olsa dahi) en fazla 1 ayl\u0131k doza kadar \u00f6denir. Sonraki re\u00e7etelerde yaz\u0131lacak ila\u00e7 miktar\u0131 i\u00e7in tebli\u011fde yer alan genel veya \u00f6zel d\u00fczenlemeler esas al\u0131n\u0131r. Bu ila\u00e7lar\u0131n devam re\u00e7etelerindeki farkl\u0131 farmas\u00f6tik dozlar\u0131 da ilk tedavi olarak kabul edilir.\u201d \u015feklinde d\u00fczenlemenin (8) numaral\u0131 f\u0131kra olarak ilave edildi\u011fi ve 28.1.2012 tarihi itibariyle y\u00fcr\u00fcrl\u00fc\u011fe girdi\u011fi, Ancak, diyaliz hastalar\u0131nda tetkik sonucuna istinaden re\u00e7ete edilen ila\u00e7lar\u0131n bir ay ve daha k\u0131sa doz i\u00e7in re\u00e7ete edilmesi halinde, Sa\u011fl\u0131k Uygulama Tebli\u011finde tarif edilen s\u00fcre i\u00e7erisinde yap\u0131lm\u0131\u015f tetkikin fotokopisinin, bir aydan daha uzun s\u00fcreli doz i\u00e7in re\u00e7ete edilmesi halinde ise ayn\u0131 tetkikin asl\u0131n\u0131n re\u00e7eteye eklenmesinin m\u00fcmk\u00fcn oldu\u011fu, bildirilmi\u015ftir. Bilgilerinizi ve konunun \u00fcyelerinize duyurulmas\u0131n\u0131 sayg\u0131lar\u0131mla rica ederim. Uzm.Ecz.Harun KIZILAY Genel Sekreter SUT 6.1.1 \u00c7 Maddesi: \u2026\u2026\u2026.. (7) (Ek: 05\/11\/2011-28106\/10 md. Y\u00fcr\u00fcrl\u00fck:17\/11\/2011) Tebli\u011fdeki \u201c1 ayl\u0131k doz\u201d; 28, 29 ve 30 g\u00fcnl\u00fck kullan\u0131m s\u00fcrelerini ifade eder. (8) (Ek: 21\/01\/2012-28180 \/20 md. Y\u00fcr\u00fcrl\u00fck: 28\/01\/2012) Hastan\u0131n tedavisinde ilk defa re\u00e7ete edilecek ila\u00e7lar (raporlu olsa dahi) en fazla 1 ayl\u0131k doza kadar \u00f6denir. Sonraki re\u00e7etelerde yaz\u0131lacak ila\u00e7 miktar\u0131 i\u00e7in tebli\u011fde yer alan genel veya \u00f6zel d\u00fczenlemeler esas al\u0131n\u0131r. Bu ila\u00e7lar\u0131n devam re\u00e7etelerindeki farkl\u0131 farmas\u00f6tik dozlar\u0131 da ilk tedavi olarak kabul edilir. http:\/\/www.teb.org.tr\/images\/upld2\/haberler\/IEc20120514081121DUY.pdf<\/p>\n","protected":false},"author":4,"featured_media":191,"comment_status":"open","ping_status":"open","sticky":false,"template":"elementor_canvas","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-4842","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-teb"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SGK BA\u015eKANLI\u011eININ DANI\u015eTAY KARARI VE D\u0130YAL\u0130Z HASTALARININ TETK\u0130K BELGELER\u0130 \u0130LE \u0130LG\u0130L\u0130 DUYURUSU HAKKINDA - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2012\/05\/14\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SGK BA\u015eKANLI\u011eININ DANI\u015eTAY KARARI VE D\u0130YAL\u0130Z HASTALARININ TETK\u0130K BELGELER\u0130 \u0130LE \u0130LG\u0130L\u0130 DUYURUSU HAKKINDA - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131\" \/>\n<meta property=\"og:description\" content=\"B\u00d6LGE ECZACI ODASI Y\u00d6NET\u0130M KURULU BA\u015eKANLI\u011eINA T.C.Sosyal G\u00fcvenlik Kurumu Ba\u015fkanl\u0131\u011f\u0131 Genel Sa\u011fl\u0131k Sigortas\u0131 Genel M\u00fcd\u00fcrl\u00fc\u011f\u00fc taraf\u0131ndan, www.sgk.gov.tr de 11.05.2012 tarihinde yay\u0131mlanan ve ekte bir \u00f6rne\u011fi yer alan duyuru ile, 1- Dan\u0131\u015ftay Onuncu Dairesinin Karar\u0131 ile, 25\/3\/2010 tarihli ve 27532 m\u00fckerrer say\u0131l\u0131 Resm\u00ee Gazetede yay\u0131mlanan Sosyal G\u00fcvenlik Kurumu Sa\u011fl\u0131k Uygulama Tebli\u011finin, 05\/11\/2011 tarih ve 28106 say\u0131l\u0131 Resm\u00ee Gazetede yay\u0131mlanan Sosyal G\u00fcvenlik Kurumu Sa\u011fl\u0131k Uygulama Tebli\u011finde De\u011fi\u015fiklik Yap\u0131lmas\u0131na Dair Tebli\u011fin 10 numaral\u0131 maddesi ile 6.1.1.\u00c7 maddesine eklenen 7 nci f\u0131kras\u0131nda yer alan \u201c28\u201d ve \u201c29\u201d ibarelerinin y\u00fcr\u00fct\u00fcm\u00fcn\u00fcn durduruldu\u011fu, 11\/05\/2012 tarihinden ba\u015flayarak Sa\u011fl\u0131k Uygulama Tebli\u011finin ilgili maddesinin bu do\u011frultuda y\u00fcr\u00fct\u00fclece\u011fi, 2- 23.1.2012 tarih, 28180 say\u0131l\u0131 Resmi Gazetede yay\u0131mlanan Sosyal G\u00fcvenlik Kurumu Sa\u011fl\u0131k Uygulama Tebli\u011finde De\u011fi\u015fiklik Yap\u0131lmas\u0131na Dair Tebli\u011fi ile 6.1.1.\u00c7-Re\u00e7etelere yaz\u0131labilecek ila\u00e7 miktarlar\u0131 ba\u015fl\u0131kl\u0131 maddesine \u201cHastan\u0131n tedavisinde ilk defa re\u00e7ete edilecek ila\u00e7lar (raporlu olsa dahi) en fazla 1 ayl\u0131k doza kadar \u00f6denir. Sonraki re\u00e7etelerde yaz\u0131lacak ila\u00e7 miktar\u0131 i\u00e7in tebli\u011fde yer alan genel veya \u00f6zel d\u00fczenlemeler esas al\u0131n\u0131r. Bu ila\u00e7lar\u0131n devam re\u00e7etelerindeki farkl\u0131 farmas\u00f6tik dozlar\u0131 da ilk tedavi olarak kabul edilir.\u201d \u015feklinde d\u00fczenlemenin (8) numaral\u0131 f\u0131kra olarak ilave edildi\u011fi ve 28.1.2012 tarihi itibariyle y\u00fcr\u00fcrl\u00fc\u011fe girdi\u011fi, Ancak, diyaliz hastalar\u0131nda tetkik sonucuna istinaden re\u00e7ete edilen ila\u00e7lar\u0131n bir ay ve daha k\u0131sa doz i\u00e7in re\u00e7ete edilmesi halinde, Sa\u011fl\u0131k Uygulama Tebli\u011finde tarif edilen s\u00fcre i\u00e7erisinde yap\u0131lm\u0131\u015f tetkikin fotokopisinin, bir aydan daha uzun s\u00fcreli doz i\u00e7in re\u00e7ete edilmesi halinde ise ayn\u0131 tetkikin asl\u0131n\u0131n re\u00e7eteye eklenmesinin m\u00fcmk\u00fcn oldu\u011fu, bildirilmi\u015ftir. Bilgilerinizi ve konunun \u00fcyelerinize duyurulmas\u0131n\u0131 sayg\u0131lar\u0131mla rica ederim. Uzm.Ecz.Harun KIZILAY Genel Sekreter SUT 6.1.1 \u00c7 Maddesi: \u2026\u2026\u2026.. (7) (Ek: 05\/11\/2011-28106\/10 md. Y\u00fcr\u00fcrl\u00fck:17\/11\/2011) Tebli\u011fdeki \u201c1 ayl\u0131k doz\u201d; 28, 29 ve 30 g\u00fcnl\u00fck kullan\u0131m s\u00fcrelerini ifade eder. (8) (Ek: 21\/01\/2012-28180 \/20 md. Y\u00fcr\u00fcrl\u00fck: 28\/01\/2012) Hastan\u0131n tedavisinde ilk defa re\u00e7ete edilecek ila\u00e7lar (raporlu olsa dahi) en fazla 1 ayl\u0131k doza kadar \u00f6denir. Sonraki re\u00e7etelerde yaz\u0131lacak ila\u00e7 miktar\u0131 i\u00e7in tebli\u011fde yer alan genel veya \u00f6zel d\u00fczenlemeler esas al\u0131n\u0131r. Bu ila\u00e7lar\u0131n devam re\u00e7etelerindeki farkl\u0131 farmas\u00f6tik dozlar\u0131 da ilk tedavi olarak kabul edilir. http:\/\/www.teb.org.tr\/images\/upld2\/haberler\/IEc20120514081121DUY.pdf\" \/>\n<meta property=\"og:url\" content=\"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2012\/05\/14\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\/\" \/>\n<meta property=\"og:site_name\" content=\"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131\" \/>\n<meta property=\"article:published_time\" content=\"2012-05-14T07:05:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-19T08:09:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/urfaeo.kolaysoft.com.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Yeni Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Yeni Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tahmini okuma s\u00fcresi\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 dakika\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/index.php\\\/2012\\\/05\\\/14\\\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/index.php\\\/2012\\\/05\\\/14\\\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\\\/\"},\"author\":{\"name\":\"Yeni Admin\",\"@id\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/#\\\/schema\\\/person\\\/f482a8288e46359eb9acced6151e1120\"},\"headline\":\"SGK BA\u015eKANLI\u011eININ DANI\u015eTAY KARARI VE D\u0130YAL\u0130Z HASTALARININ TETK\u0130K BELGELER\u0130 \u0130LE \u0130LG\u0130L\u0130 DUYURUSU HAKKINDA\",\"datePublished\":\"2012-05-14T07:05:00+00:00\",\"dateModified\":\"2026-01-19T08:09:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/index.php\\\/2012\\\/05\\\/14\\\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\\\/\"},\"wordCount\":466,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/index.php\\\/2012\\\/05\\\/14\\\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/urfaeo-logo2.png\",\"articleSection\":[\"TEB\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/index.php\\\/2012\\\/05\\\/14\\\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/index.php\\\/2012\\\/05\\\/14\\\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\\\/\",\"url\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/index.php\\\/2012\\\/05\\\/14\\\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\\\/\",\"name\":\"SGK BA\u015eKANLI\u011eININ DANI\u015eTAY KARARI VE D\u0130YAL\u0130Z HASTALARININ TETK\u0130K BELGELER\u0130 \u0130LE \u0130LG\u0130L\u0130 DUYURUSU HAKKINDA - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/index.php\\\/2012\\\/05\\\/14\\\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/index.php\\\/2012\\\/05\\\/14\\\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/urfaeo-logo2.png\",\"datePublished\":\"2012-05-14T07:05:00+00:00\",\"dateModified\":\"2026-01-19T08:09:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/index.php\\\/2012\\\/05\\\/14\\\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\\\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/index.php\\\/2012\\\/05\\\/14\\\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/index.php\\\/2012\\\/05\\\/14\\\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\\\/#primaryimage\",\"url\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/urfaeo-logo2.png\",\"contentUrl\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/urfaeo-logo2.png\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/index.php\\\/2012\\\/05\\\/14\\\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Anasayfa\",\"item\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SGK BA\u015eKANLI\u011eININ DANI\u015eTAY KARARI VE D\u0130YAL\u0130Z HASTALARININ TETK\u0130K BELGELER\u0130 \u0130LE \u0130LG\u0130L\u0130 DUYURUSU HAKKINDA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/#website\",\"url\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/\",\"name\":\"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/#organization\",\"name\":\"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131\",\"url\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/22022021211638-19929-73208.png\",\"contentUrl\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/22022021211638-19929-73208.png\",\"width\":635,\"height\":635,\"caption\":\"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131\"},\"image\":{\"@id\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/#\\\/schema\\\/person\\\/f482a8288e46359eb9acced6151e1120\",\"name\":\"Yeni Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g\",\"caption\":\"Yeni Admin\"},\"url\":\"https:\\\/\\\/urfaeo.kolaysoft.com.tr\\\/index.php\\\/author\\\/yeniadmin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SGK BA\u015eKANLI\u011eININ DANI\u015eTAY KARARI VE D\u0130YAL\u0130Z HASTALARININ TETK\u0130K BELGELER\u0130 \u0130LE \u0130LG\u0130L\u0130 DUYURUSU HAKKINDA - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2012\/05\/14\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\/","og_locale":"tr_TR","og_type":"article","og_title":"SGK BA\u015eKANLI\u011eININ DANI\u015eTAY KARARI VE D\u0130YAL\u0130Z HASTALARININ TETK\u0130K BELGELER\u0130 \u0130LE \u0130LG\u0130L\u0130 DUYURUSU HAKKINDA - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131","og_description":"B\u00d6LGE ECZACI ODASI Y\u00d6NET\u0130M KURULU BA\u015eKANLI\u011eINA T.C.Sosyal G\u00fcvenlik Kurumu Ba\u015fkanl\u0131\u011f\u0131 Genel Sa\u011fl\u0131k Sigortas\u0131 Genel M\u00fcd\u00fcrl\u00fc\u011f\u00fc taraf\u0131ndan, www.sgk.gov.tr de 11.05.2012 tarihinde yay\u0131mlanan ve ekte bir \u00f6rne\u011fi yer alan duyuru ile, 1- Dan\u0131\u015ftay Onuncu Dairesinin Karar\u0131 ile, 25\/3\/2010 tarihli ve 27532 m\u00fckerrer say\u0131l\u0131 Resm\u00ee Gazetede yay\u0131mlanan Sosyal G\u00fcvenlik Kurumu Sa\u011fl\u0131k Uygulama Tebli\u011finin, 05\/11\/2011 tarih ve 28106 say\u0131l\u0131 Resm\u00ee Gazetede yay\u0131mlanan Sosyal G\u00fcvenlik Kurumu Sa\u011fl\u0131k Uygulama Tebli\u011finde De\u011fi\u015fiklik Yap\u0131lmas\u0131na Dair Tebli\u011fin 10 numaral\u0131 maddesi ile 6.1.1.\u00c7 maddesine eklenen 7 nci f\u0131kras\u0131nda yer alan \u201c28\u201d ve \u201c29\u201d ibarelerinin y\u00fcr\u00fct\u00fcm\u00fcn\u00fcn durduruldu\u011fu, 11\/05\/2012 tarihinden ba\u015flayarak Sa\u011fl\u0131k Uygulama Tebli\u011finin ilgili maddesinin bu do\u011frultuda y\u00fcr\u00fct\u00fclece\u011fi, 2- 23.1.2012 tarih, 28180 say\u0131l\u0131 Resmi Gazetede yay\u0131mlanan Sosyal G\u00fcvenlik Kurumu Sa\u011fl\u0131k Uygulama Tebli\u011finde De\u011fi\u015fiklik Yap\u0131lmas\u0131na Dair Tebli\u011fi ile 6.1.1.\u00c7-Re\u00e7etelere yaz\u0131labilecek ila\u00e7 miktarlar\u0131 ba\u015fl\u0131kl\u0131 maddesine \u201cHastan\u0131n tedavisinde ilk defa re\u00e7ete edilecek ila\u00e7lar (raporlu olsa dahi) en fazla 1 ayl\u0131k doza kadar \u00f6denir. Sonraki re\u00e7etelerde yaz\u0131lacak ila\u00e7 miktar\u0131 i\u00e7in tebli\u011fde yer alan genel veya \u00f6zel d\u00fczenlemeler esas al\u0131n\u0131r. Bu ila\u00e7lar\u0131n devam re\u00e7etelerindeki farkl\u0131 farmas\u00f6tik dozlar\u0131 da ilk tedavi olarak kabul edilir.\u201d \u015feklinde d\u00fczenlemenin (8) numaral\u0131 f\u0131kra olarak ilave edildi\u011fi ve 28.1.2012 tarihi itibariyle y\u00fcr\u00fcrl\u00fc\u011fe girdi\u011fi, Ancak, diyaliz hastalar\u0131nda tetkik sonucuna istinaden re\u00e7ete edilen ila\u00e7lar\u0131n bir ay ve daha k\u0131sa doz i\u00e7in re\u00e7ete edilmesi halinde, Sa\u011fl\u0131k Uygulama Tebli\u011finde tarif edilen s\u00fcre i\u00e7erisinde yap\u0131lm\u0131\u015f tetkikin fotokopisinin, bir aydan daha uzun s\u00fcreli doz i\u00e7in re\u00e7ete edilmesi halinde ise ayn\u0131 tetkikin asl\u0131n\u0131n re\u00e7eteye eklenmesinin m\u00fcmk\u00fcn oldu\u011fu, bildirilmi\u015ftir. Bilgilerinizi ve konunun \u00fcyelerinize duyurulmas\u0131n\u0131 sayg\u0131lar\u0131mla rica ederim. Uzm.Ecz.Harun KIZILAY Genel Sekreter SUT 6.1.1 \u00c7 Maddesi: \u2026\u2026\u2026.. (7) (Ek: 05\/11\/2011-28106\/10 md. Y\u00fcr\u00fcrl\u00fck:17\/11\/2011) Tebli\u011fdeki \u201c1 ayl\u0131k doz\u201d; 28, 29 ve 30 g\u00fcnl\u00fck kullan\u0131m s\u00fcrelerini ifade eder. (8) (Ek: 21\/01\/2012-28180 \/20 md. Y\u00fcr\u00fcrl\u00fck: 28\/01\/2012) Hastan\u0131n tedavisinde ilk defa re\u00e7ete edilecek ila\u00e7lar (raporlu olsa dahi) en fazla 1 ayl\u0131k doza kadar \u00f6denir. Sonraki re\u00e7etelerde yaz\u0131lacak ila\u00e7 miktar\u0131 i\u00e7in tebli\u011fde yer alan genel veya \u00f6zel d\u00fczenlemeler esas al\u0131n\u0131r. Bu ila\u00e7lar\u0131n devam re\u00e7etelerindeki farkl\u0131 farmas\u00f6tik dozlar\u0131 da ilk tedavi olarak kabul edilir. http:\/\/www.teb.org.tr\/images\/upld2\/haberler\/IEc20120514081121DUY.pdf","og_url":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2012\/05\/14\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\/","og_site_name":"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131","article_published_time":"2012-05-14T07:05:00+00:00","article_modified_time":"2026-01-19T08:09:32+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/urfaeo.kolaysoft.com.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","type":"image\/png"}],"author":"Yeni Admin","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Yeni Admin","Tahmini okuma s\u00fcresi":"2 dakika"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2012\/05\/14\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\/#article","isPartOf":{"@id":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2012\/05\/14\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\/"},"author":{"name":"Yeni Admin","@id":"https:\/\/urfaeo.kolaysoft.com.tr\/#\/schema\/person\/f482a8288e46359eb9acced6151e1120"},"headline":"SGK BA\u015eKANLI\u011eININ DANI\u015eTAY KARARI VE D\u0130YAL\u0130Z HASTALARININ TETK\u0130K BELGELER\u0130 \u0130LE \u0130LG\u0130L\u0130 DUYURUSU HAKKINDA","datePublished":"2012-05-14T07:05:00+00:00","dateModified":"2026-01-19T08:09:32+00:00","mainEntityOfPage":{"@id":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2012\/05\/14\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\/"},"wordCount":466,"commentCount":0,"publisher":{"@id":"https:\/\/urfaeo.kolaysoft.com.tr\/#organization"},"image":{"@id":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2012\/05\/14\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\/#primaryimage"},"thumbnailUrl":"https:\/\/urfaeo.kolaysoft.com.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","articleSection":["TEB"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2012\/05\/14\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2012\/05\/14\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\/","url":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2012\/05\/14\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\/","name":"SGK BA\u015eKANLI\u011eININ DANI\u015eTAY KARARI VE D\u0130YAL\u0130Z HASTALARININ TETK\u0130K BELGELER\u0130 \u0130LE \u0130LG\u0130L\u0130 DUYURUSU HAKKINDA - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131","isPartOf":{"@id":"https:\/\/urfaeo.kolaysoft.com.tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2012\/05\/14\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\/#primaryimage"},"image":{"@id":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2012\/05\/14\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\/#primaryimage"},"thumbnailUrl":"https:\/\/urfaeo.kolaysoft.com.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","datePublished":"2012-05-14T07:05:00+00:00","dateModified":"2026-01-19T08:09:32+00:00","breadcrumb":{"@id":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2012\/05\/14\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2012\/05\/14\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2012\/05\/14\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\/#primaryimage","url":"https:\/\/urfaeo.kolaysoft.com.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","contentUrl":"https:\/\/urfaeo.kolaysoft.com.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/2012\/05\/14\/sgk-baskanliginin-danistay-karari-ve-diyaliz-hastalarinin-tetkik-belgeleri-ile-ilgili-duyurusu-hakkinda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Anasayfa","item":"https:\/\/urfaeo.kolaysoft.com.tr\/"},{"@type":"ListItem","position":2,"name":"SGK BA\u015eKANLI\u011eININ DANI\u015eTAY KARARI VE D\u0130YAL\u0130Z HASTALARININ TETK\u0130K BELGELER\u0130 \u0130LE \u0130LG\u0130L\u0130 DUYURUSU HAKKINDA"}]},{"@type":"WebSite","@id":"https:\/\/urfaeo.kolaysoft.com.tr\/#website","url":"https:\/\/urfaeo.kolaysoft.com.tr\/","name":"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131","description":"","publisher":{"@id":"https:\/\/urfaeo.kolaysoft.com.tr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/urfaeo.kolaysoft.com.tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Organization","@id":"https:\/\/urfaeo.kolaysoft.com.tr\/#organization","name":"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131","url":"https:\/\/urfaeo.kolaysoft.com.tr\/","logo":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/urfaeo.kolaysoft.com.tr\/#\/schema\/logo\/image\/","url":"https:\/\/urfaeo.kolaysoft.com.tr\/wp-content\/uploads\/2025\/09\/22022021211638-19929-73208.png","contentUrl":"https:\/\/urfaeo.kolaysoft.com.tr\/wp-content\/uploads\/2025\/09\/22022021211638-19929-73208.png","width":635,"height":635,"caption":"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131"},"image":{"@id":"https:\/\/urfaeo.kolaysoft.com.tr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/urfaeo.kolaysoft.com.tr\/#\/schema\/person\/f482a8288e46359eb9acced6151e1120","name":"Yeni Admin","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g","caption":"Yeni Admin"},"url":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/author\/yeniadmin\/"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/wp-json\/wp\/v2\/posts\/4842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/wp-json\/wp\/v2\/comments?post=4842"}],"version-history":[{"count":0,"href":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/wp-json\/wp\/v2\/posts\/4842\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/wp-json\/wp\/v2\/media\/191"}],"wp:attachment":[{"href":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/wp-json\/wp\/v2\/media?parent=4842"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/wp-json\/wp\/v2\/categories?post=4842"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/urfaeo.kolaysoft.com.tr\/index.php\/wp-json\/wp\/v2\/tags?post=4842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}